---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060449"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:44:43.812843+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# enGene Holdings shareholders approve amended 2023 Incentive Equity Plan

## Summary
- Shareholders approved amended 2023 Incentive Equity Plan with 25,623,625 votes for and 2,586,367 against at May 15 annual meeting.
- Plan amendment changes evergreen provision to annual increase of 5% of outstanding common shares (or smaller as determined by committee).
- Directors Paul Hastings (28,201,063 for), Wouter Joustra (28,212,507 for), and Lota Zoth (28,212,007 for) elected.
- Appointment of auditor approved with 28,467,217 votes for, no against or abstentions.
- Amended plan filed as Exhibit 10.1; effective upon shareholder approval.

## SEC filing metadata
- accession: 0000950170-24-060449
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/0000950170-24-060449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/engn-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060449
- JSON: https://secwatch.observer/filing/0000950170-24-060449.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060449.txt

## Key facts
- Shareholder Votes
  enGene Therapeutics Inc. shareholders approved Approval of Amendment of the enGene Holdings Inc. Incentive Equity Plan at the 2024-05-15 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2024-05-15
  source text: Proposal 2 – Approval of Amendment of the enGene Holdings Inc. Incentive Equity Plan For Against Abstain Broker Non-Votes 25,623,625 2,586,367 2,515 254,710
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/0000950170-24-060449-index.htm
- Shareholder Votes
  enGene Therapeutics Inc. shareholders approved Election of Directors at the 2024-05-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2024-05-15
  source text: Proposal 1 – Election of Directors Director Nominee For Withhold Broker Non-Votes Paul Hastings 28,201,063 11,444 254,710 Wouter Joustra 28,212,507 - 254,710 Lota Zoth 28,212,007 500 254,710
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/0000950170-24-060449-index.htm
- Shareholder Votes
  enGene Therapeutics Inc. shareholders approved Appointment and Remuneration of Auditor at the 2024-05-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2024-05-15
  source text: Proposal 3 – Appointment and Renumeration of Auditor For Withhold Broker Non-Votes 28,467,217 - -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/0000950170-24-060449-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.